Research and Development
Strong, Innovation-driven R&D Capabilities
10 Compounds
in the Pipeline
7Compounds
in clinical studies
62 Patent
Authorizations

from China and the Patent
Cooperation Treaty
6 Major New Drug Invention Projects
under the Major National Science and Technology
Special Program and 8 Projects in Shanghai’s Science
and Technology Innovation Action Plan
R&D Field
Cancer Types Covered by the R&D Pipeline
 
  • Lung
    Cancer
  • Breast
    Cancer
  • Gastric
    Cancer
  • Nasopharyngeal
    Cancer
Rich and Balanced Product Line
Updated in October 2020
 
  • 10 compounds, including those in late clinical stage and pre-clinical stage
  • The compound targets in the late stage of development have been verified
  • Multiple potential best-in-class compounds are expected to be used in combination to treat major indications
Outstanding Talent
  • Leading scientists with outstanding achievements
  • Rich experience in successful drug approval & launch
  • Covering the entire span of oncology research and development
R&D Pipeline
Clinical Stage
 
Pipeline Profile Target Indication/
Potential indication
Rights Stage

Pre-clinical

 

Phase 1

 

Phase 2

 

Phase 3

 

NDA

Country/region
where the
product is launched
RMX3001
(Liporaxel)

Microtubule Stabilizer

It is the 1st oral paclitaxel developed globally. Its safety and ease of administration are expected to bring significant improvements to cancer patients. Based on the unique innovative process technology, it is absorbed through the gastrointestinal tract, thus avoiding premedication, and reducing side effects such as peripheral neuropathy.

NA Gastric Cancer China           Approved in Korea 
Breast Cancer China            
ON101

TCM

Reduce wound inflammation Increase epithelialization of epidermal tissues Promote collagen production Reduce formation of wound granulation tissues

NA Diabetic Foot Ulcer Mainland, China         Taiwan, China  
Lucitanib

Oral small molecule TKI targeting FGFR1-3, VEGFR1-3, PDGFR α/β, with significant efficacy and high safety Rapid oral absorption, with little food effects on PK Pivotal Phase II study ongoing in multiple sites nationwide for the treatment of various types of tumors Explore combinations with PD-1/PD-L1 antibody

FGFR1-3 Thymic Cancer Mainland, China      Pivotal Phase 2       
VEGFR1-3 Nasopharyngeal Carcinoma Mainland, China    in Combination with PD-1  Pivotal Phase 2, in combination with PD-1      
PDGFR α/β Small Cell Lung Cancer Mainland, China      n combination with chemothin combination with chemotherapyerapy      
Glumetinib

Clinical development strategy guided by unique biomarkers High selectivity to c-Met and long half-life Multiple studies ongoing in China/Japan/US; preliminary clinical efficacy hasbeen observed, with good safety

c-Met c-Met in Non-small Cell Lung Cancer Global            
Exon-14 Skipping in Non-small Cell Lung Cancer Global      Pivotal Phase 2(China / Japan / US)      
c-Met Mutation in Non-small Cell Lung Cancer Global      in combination with PD-1 in combination with EGFR inhibitor (Asia)      
CYH33

Highly active PI3Kα inhibitor Clinical development strategy guided by unique biomarkers Significant in vivo/vitro anti-tumor effects Preferable safety profile with little and reversible glycemia effects

PI3Kα Oncology Global            
Pipeline
Profile

Microtubule Stabilizer

It is the 1st oral paclitaxel developed globally. Its safety and ease of administration are expected to bring significant improvements to cancer patients. Based on the unique innovative process technology, it is absorbed through the gastrointestinal tract, thus avoiding premedication, and reducing side effects such as peripheral neuropathy.

Target

N/A

Indication/ Potential indication 

Gastric Cancer

  • Stage

    Pre-clinical 

     
  •  

    Phase 1

     
  •  

    Phase 2

     
  •  

    Phase 3

     
  •  

    NDA

Breast Cancer

  • Stage

    Pre-clinical 

     
  •  

    Phase 1

     
  •  

    Phase 2

     
  •  

    Phase 3

     
  •  

    NDA

Country / region where the product is launched 

Approved in Korea 

特性

中藥

降低傷口發炎反應、增加表皮組織上皮化、促進膠原蛋白生成、減少傷口肉芽組織生成

靶點

N/A

適應癥 及潛在 適應癥

糖尿病足潰瘍

  • 階段

    臨床前

  •  

    1期

     
  •  

    2期

     
  •  

    3期

     
  •  

    上市申請

特性

療效顯著,安全性高的多靶點口服小分子激酶抑制劑;口服給藥吸收快,食物對藥代動力學的影響不顯著;關鍵性II期臨床試驗正在全國多家中心開展,涵蓋多瘤種;正在開展包括PD-1/ PD-L1抗體在內的多種聯合治療探索

靶點

FGFR1-3

適應癥 及潛在 適應癥

胸腺癌

  • 階段

    臨床前

     
  •  

    1期

     
  •  

    2期

     
  •  

    3期

  •  

    上市申請

靶點

VEGFR1-3

適應癥 及潛在 適應癥

鼻咽癌

  • 階段

    臨床前

     
  •  

    1期

     
  •  

    2期

     
  •  

    3期

  •  

    上市申請

靶點

PDGFR α/β

適應癥 及潛在 適應癥

小細胞肺癌

  • 階段

    臨床前

     
  •  

    1期

     
  •  

    2期

     
  •  

    3期

     
  •  

    上市申請

特性

獨特生物標記物指導臨床開發;對c-Met選擇性高,半衰期長;多項臨床試驗在中國/日本/美國進行

靶點

c-Met

適應癥 及潛在 適應癥

c-Met非小細胞肺癌

  • 階段

    臨床前

     
  •  

    1期

     
  •  

    2期

     
  •  

    3期

  •  

    上市申請

Exon-14跳躍非小細胞肺癌

  • 階段

    臨床前

     
  •  

    1期

     
  •  

    2期

     
  •  

    3期

  •  

    上市申請

c-Met變異非小細胞肺癌

  • 階段

    臨床前

     
  •  

    1期

     
  •  

    2期

     
  •  

    3期

  •  

    上市申請

特性

活性顯著的高選擇性PI3Kα抑制劑;獨特生物標志物指導臨床開發;顯著的體內/外抗腫瘤作用;藥物安全可控,對血糖影響小且可逆

靶點

PI3Kα

適應癥 及潛在 適應癥

腫瘤

  • 階段

    臨床前

     
  •  

    1期

     
  •  

    2期

  •  

    3期

  •  

    上市申請

Follow Us
?2020 Shanghai Haihe Biopharma Research and Development Co., Ltd.
All Rights Reserved 滬ICP備12016151號-1
国产高清亚洲精品视频_国产亚洲精品香蕉视频播放_国产网红精品福利视频